Common Stock
- Symbol
- NVCT
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Nuvectis Pharma, Inc.
NVCTNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 4, 2026, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June 30, 2026. A copy of such press release is being furnished as Exhibit 99.1 to this report.…
Press release in this filing
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights →Company context
Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company’s pipeline includes ciprocopan (NXP100), a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP900 and NXP200, in development for the treatment of advanced cancers.
Current securities
Registered securities in this filing
Nuvectis Pharma, Inc. · 8-K · Filed 2026-08-04
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition.
On August 4, 2026, Nuvectis
Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June
30, 2026. A copy of such press release is being furnished as Exhibit 99.1 to this report.
The information, including
Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not
be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly set
forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 2 tm2622125d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group (“Haisco”), transforming the company into a late-stage clinical development organization. The Company’s lead drug candidate, ciprocopan (NXP100), a Complement Factor B inhibitor for once-daily, oral administration, was approved in China in July 2026 for the treatment of patients with PNH previously untreated with complement inhibitors. ───────────────────────────────────────────────────────────────────────────────────────────── Completed follow-on offering in July 2026, raising $115M in gross proceeds. Transaction anchored by leading healthcare dedicated investors and extends cash runway into 1H 2029. August 4, 2026, Fort Lee, NJ - Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today reported its…
Open exhibit ↗